Vestigial like family member 3 is a novel prognostic biomarker for gastric cancer

Figure 1 Vestigial like family member 3 mRNA expression levels in gastric cancer tissues determined by integrated analysis of different databases. A and B: Vestigial like family member 3 (VGLL3) expression in gastric cancer and normal gastric tissues (A) and in different TNM stages (B) in the GEPIA database; C: VGLL3 expression reported in the five published studies in the ONCOMINE database; D and E: Kaplan-Meier survival analysis of patients in the GEPIA (D) and ONCOLNC (E) databases stratified by VGLL3 expression status.

Figure 2 Vestigial like family member 3 mRNA and protein expression levels in gastric cancer. The expression of vestigial like family member 3 mRNA (A) and protein (B and C) in 30 pairs of gastric cancer and normal gastric tissues is shown.

Figure 3 Prognostic value and putative molecular mechanism of vestigial like family member 3 in gastric cancer. A-D: HER2 mutation status detected by FISH (A and C) and IHC (B and D) in gastric cancer (GC) tissues; E and F: In situ vestigial like family member 3 (VGLL3) status in GC tissues; G: Kaplan-Meier survival analysis on patients stratified by VGLL3 expression status; H: Prognostic nomogram for gastric cancer based on VGLL3 expression status and clinical features; I: Time-dependent receiver operating characteristic curves for the combination of VGLL3-based prognostic score and clinico-pathological variables; J: Protein-protein interaction network of VGLL3 based on STRING database.